CORONA Remedies Key Ratios
NSE: CORONA | BSE: 544644
₹2,100.10
₹-27.70
(-1.30%)
As on 04-Sep-2026 15:56IST
Market cap
₹12,843 Cr
Revenue (TTM)
₹1,479 Cr
P/E Ratio
64.5
P/B Ratio
15.9
Div. Yield
0.5 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 19.64 | 21.90 | 18.16 | 16.65 | 19.49 |
| EBIT | 54.44 | 31.27 | 23.39 | 33.31 | 23.35 |
| Net Profit | 32.61 | 30.11 | 28.76 | 29.71 | 21.45 |
| EPS | 32.61 | 30.11 | 20.14 | 29.71 | 17.14 |
| Book Value | -- | -- | 23.15 | 22.29 | 13.04 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 15.88 | 11.88 | 18.57 | 18.21 | 16.95 |
| Net Margin
| 11.45 | 8.76 | 13.32 | 13.09 | 12.43 |
| Return on equity
| 25.06 | 19.66 | 30.33 | 27.36 | 27.50 |
| Return on Capital
| 30.07 | 24.27 | -- | 31.74 | 32.59 |
| Return on Assets
| 14.50 | 11.47 | 32.95 | 15.99 | 15.79 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.19 | 0.10 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
--
|
31.74
|
32.59
|
25.93
|
28.03
|
||||||
|
Peer Median
|
--
|
19.34
|
21.76
|
21.89
|
--
|
17.36
|
|
|
|
|
|
ROE
30.33
Higher than Peers by 14.98
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
30.33
|
27.36
|
27.50
|
20.36
|
20.79
|
||||||
|
Peer Median
|
15.35
|
17.67
|
17.93
|
16.42
|
--
|
17.35
|
|
|
|
|
|
ROA
32.95
Higher than Peers by 22.60
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
32.95
|
15.99
|
15.79
|
11.77
|
12.82
|
||||||
|
Peer Median
|
10.35
|
9.88
|
12.81
|
12.32
|
--
|
10.65
|
|
|
|
|
|
EBIT Margin
18.57
Higher than Peers by 0.56
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
18.57
|
18.21
|
16.95
|
12.47
|
12.20
|
||||||
|
Peer Median
|
18.01
|
18.96
|
18.93
|
21.05
|
--
|
11.27
|
|
|
|
|
|
Net Margin
13.32
Lower than Peers by 1.14
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
13.32
|
13.09
|
12.43
|
8.86
|
9.53
|
||||||
|
Peer Median
|
14.45
|
13.32
|
14.94
|
15.51
|
--
|
11.45
|
|
|
|
|
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
--
|
16.17
|
15.88
|
11.45
|
11.69
|
||||||
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Revenue Growth
18.16
Higher than Peers by 6.21
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
18.16
|
17.28
|
17.94
|
14.75
|
--
|
||||||
|
Peer Median
|
11.95
|
12.97
|
10.90
|
13.44
|
--
|
11.49
|
|
|
|
|
|
EBIT Growth
23.39
Higher than Peers by 1.80
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
23.39
|
26.01
|
60.39
|
17.22
|
--
|
||||||
|
Peer Median
|
21.60
|
15.05
|
15.01
|
23.50
|
--
|
-1.10
|
|
|
|
|
|
Net Profit Growth
28.76
Higher than Peers by 6.02
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
28.76
|
23.88
|
65.11
|
6.56
|
--
|
||||||
|
Peer Median
|
22.73
|
11.89
|
14.80
|
30.12
|
--
|
4.90
|
|
|
|
|
|
EPS Growth
20.14
Higher than Peers by 0.11
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
20.14
|
23.88
|
65.11
|
6.56
|
--
|
||||||
|
Peer Median
|
20.03
|
12.16
|
14.27
|
29.02
|
--
|
10.00
|
|
|
|
|
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
--
|
23.18
|
26.21
|
17.60
|
--
|
||||||
|
Peer Median
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
--
|
0.19
|
0.10
|
0.28
|
0.01
|
||||||
|
Peer Median
|
0.00
|
0.05
|
0.06
|
0.03
|
--
|
0.18
|
|
|
|
|
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
--
|
0.17
|
0.02
|
0.06
|
0.01
|
||||||
|
Peer Median
|
Current Ratio
0.96
Lower than Peers by 1.12
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
0.96
|
0.97
|
1.30
|
1.24
|
1.74
|
||||||
|
Peer Median
|
2.08
|
1.93
|
1.90
|
2.23
|
--
|
1.72
|
|
|
|
|
|
Quick Ratio
0.62
Lower than Peers by 0.92
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
0.62
|
0.70
|
0.91
|
0.88
|
1.23
|
||||||
|
Peer Median
|
1.54
|
1.52
|
1.46
|
1.59
|
--
|
1.41
|
|
|
|
|
|
Interest Coverage
34.89
Higher than Peers by 15.52
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
34.89
|
35.49
|
19.73
|
9.21
|
26.98
|
||||||
|
Peer Median
|
19.38
|
19.95
|
24.96
|
45.29
|
--
|
24.64
|
|
|
|
|
|
Operating Efficiency
Debtors to sales
9.84
Lower than Peers by 11.54
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
9.84
|
10.37
|
9.89
|
9.85
|
9.84
|
||||||
|
Peer Median
|
21.38
|
19.87
|
21.77
|
20.10
|
--
|
23.77
|
|
|
|
|
|
Asset Turnover
2.45
Higher than Peers by 1.73
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
2.45
|
1.19
|
1.24
|
1.35
|
1.36
|
||||||
|
Peer Median
|
0.72
|
0.77
|
0.76
|
0.81
|
--
|
1.05
|
|
|
|
|
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
--
|
34.91
|
33.89
|
32.89
|
35.35
|
||||||
|
Peer Median
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
--
|
33.67
|
35.38
|
35.85
|
42.83
|
||||||
|
Peer Median
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
--
|
203.24
|
198.93
|
167.89
|
163.28
|
||||||
|
Peer Median
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
--
|
-134.66
|
-129.66
|
-99.14
|
-85.10
|
||||||
|
Peer Median
|
Valuation
Price / Earnings
64.53
Higher than Peers by 29.60
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
64.53
|
51.41
|
--
|
--
|
--
|
||||||
|
Peer Median
|
34.93
|
34.81
|
26.81
|
39.85
|
--
|
26.65
|
|
|
|
|
|
Price / Book Value
15.92
Higher than Peers by 10.65
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
15.92
|
12.74
|
--
|
--
|
--
|
||||||
|
Peer Median
|
5.27
|
5.65
|
4.65
|
6.11
|
--
|
3.55
|
|
|
|
|
|
Dividend Yield
0.48
Higher than Peers by 0.17
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
0.48
|
0.64
|
--
|
--
|
--
|
||||||
|
Peer Median
|
0.31
|
0.47
|
0.61
|
0.37
|
--
|
0.04
|
|
|
|
|
|
EV/EBITDA
39.39
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
39.39
|
31.62
|
0.22
|
0.78
|
-0.10
|
||||||
|
Peer Median
|
--
|
29.44
|
27.02
|
34.57
|
--
|
17.31
|
|
|
|
|
|
Market Cap
12,843
Lower than Peers by 8,264
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
12,843
|
9,517
|
--
|
--
|
--
|
||||||
|
Peer Median
|
21,107
|
18,631
|
20,914
|
25,297
|
--
|
474
|
|
|
|
|
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
